Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04472338 · ClinicalTrials.gov registry record
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
A clinical trial of Prostate Carcinoma, sponsored by University of Washington.
- Recruiting
- Registry status
- 450
- Enrollment target
- 8
- Study locations
NCT04472338: Recruiting study of Prostate Carcinoma, sponsored by University of Washington.
NCT04472338 is a study of Prostate Carcinoma that is actively recruiting participants, run by University of Washington. The registered enrollment target is 450 participants, below the 1,494-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (70% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04472338, a study of Prostate Carcinoma, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.
Primary Outcome
To estimate PPVs of age-based PSA thresholds for biopsy referral in this patient population, will first fit a logistic regression model to estimate the odds that biopsy leads to a prostate cancer diagnosis. The regression will have a binary indicator of prostate cancer diagnosis as the response variable, patient age at biopsy (categorized as \< 50, 50-59, or \>= 60 years to correspond to the age-based PSA thresholds) as a fixed effect, and a unique patient identifier as a random effect to accoun
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
Study Locations (8)
California
- City of Hope - Duarte
- University of California, San Francisco - San Francisco
Illinois
- Northwestern - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Oregon
- OHSU Knight Cancer Institute - Portland
Pennsylvania
- University of Pennsylvania/Abramson Cancer Center - Philadelphia
Texas
- University of Texas Health Science Center at San Antonio - San Antonio
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2020-05-21 |
| Est. Completion | 2030-08-31 |
What NCT04472338 shows while recruiting
NCT04472338 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 1,494-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT04472338 lists 8 locations in 7 states (California, Illinois, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04472338 about?
NCT04472338 is a clinical study titled "Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study". This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help iden...
What is the current status of trial NCT04472338?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2020-05-21. Estimated completion is 2030-08-31.
What conditions does trial NCT04472338 study?
This clinical trial studies the following conditions: Prostate Carcinoma.
What interventions are being tested in trial NCT04472338?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT04472338?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04472338 being conducted?
This trial has 8 study locations across California, Illinois, Massachusetts, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04472338's enrollment target sits among peer trials
450 8th of 59 higher than 52 of 59 other Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
RECRUITING · NA
-
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
RECRUITING · Early Phase 1
-
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
RECRUITING
-
An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
RECRUITING · Phase 2
-
Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
RECRUITING · Early Phase 1
-
Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI